- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07836660
A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI355 in participants with moderate-to-severe Sj?gren's disease (SjD).
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This study is a randomized, double-blind, placebo-controlled Phase II study in participants with moderate-to-severe Sjögren's disease. Eligible participants will be randomized to receive IBI355 or placebo during the double-blind treatment period.
The study will evaluate the efficacy of IBI355 in reducing systemic disease activity and improving patient-reported symptoms and disease-related functional outcomes. Safety and tolerability will be assessed throughout the study. Pharmacokinetic, immunogenicity, pharmacodynamic, and other relevant clinical assessments will also be performed as specified in the protocol.
The results of this study are intended to characterize the efficacy and safety profile of IBI355 in participants with Sjögren's disease and to support its further clinical development.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: xiaoyan li
- Telefonnummer: 18756032014
- E-post: xiaoyan.li@innoventbio.com
Studieorter
-
-
Anhui
-
Hefei, Anhui, Kina, 230001
- The First Affiliated Hospital of University of Science and Technology of China
-
Huvudutredare:
- Xiaomei Li, M.D.
-
Kontakt:
- Xiaomei Li
- Telefonnummer: 13866795533
- E-post: lixiaomei@fsmy@aliyun.com
-
Underutredare:
- Zhen Tan, M.D.
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥18 and ≤75 years.
- Diagnosis of Sjögren's syndrome per 2016 ACR/EULAR classification criteria.
- Duration of Sjögren's syndrome diagnosis ≤7.5 years.
- Serum anti-Ro/SSA (Ro60 and/or Ro52) positive.
- Stimulated whole saliva flow rate ≥0.05 mL/min at screening.
- Baseline ESSDAI score ≥5 in ≥1 of the following domains: systemic, lymphadenopathy, glandular, articular, cutaneous, renal, hematologic, biological.
- Stable background therapy (hydroxychloroquine ≤400 mg/day, methotrexate ≤25 mg/week, or azathioprine ≤150 mg/day) for ≥12 weeks with stable dose ≥8 weeks prior to randomization.
- Stable oral corticosteroid dose (≤10 mg/day prednisone equivalent) for ≥4 weeks prior to randomization.
Exclusion Criteria:
- Known hypersensitivity to IBI355 or its excipients.
- Pregnancy or breastfeeding.
- Uncontrolled interstitial lung disease (ILD) associated with Sjögren's syndrome (e.g., FVC <70% predicted, ClinESSDAI pulmonary domain indicating severe activity, or NYHA Class III/IV dyspnea).
- Active or untreated latent tuberculosis (IGRA-positive without ≥1 month prophylactic treatment).
- Chronic hepatitis B (HBsAg+), hepatitis C (HCV RNA+), HIV, or syphilis.
- Prior use of rituximab, other anti-CD20 agents, or other biologics targeting CD40/CD40L, BAFF/APRIL, or CTLA-4 within 6 months prior to randomization.
- Use of JAK/TYK inhibitors within 8 weeks prior to randomization.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part A: IBI355 group
IBI355,IV,corresponding dose regimen according to study cohort( Part A) . |
Matching placebo of IBI355, IV ,corresponding dose regimen according to study design IBI355,IV,corresponding dose regimen according to study design |
|
Experimentell: Part B: Telitacicept 160 mg group
Participants received telitacicept 160 mg SC QW from Week 0 to Week 24. Follow-up through Week 36 |
Telitacicept 160 mg SC QW × 24 doses (Weeks 0-24). |
|
Experimentell: Part A: Placebo group(IBI355-matched)
Matching placebo of IBI355, IV ,corresponding dose regimen according to study design |
Matching placebo of IBI355, IV ,corresponding dose regimen according to study design IBI355,IV,corresponding dose regimen according to study design |
|
Experimentell: Part B: Placebo group (Telitacicept-matched)
Participants received matching placebo SC QW from Week 0 to Week 24. Follow-up through Week 36. |
Matching placebo of Talitacicept ,SC QW × 24 doses. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 24
Tidsram: Baseline and Week 24
|
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is a physician-assessed index used to evaluate systemic disease activity in Sjögren's disease. The total score ranges from 0 to 123, with higher scores indicating greater systemic disease activity. A decrease from baseline indicates improvement. |
Baseline and Week 24
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from Baseline in ESSDAI Score at Weeks 12 and 48
Tidsram: Baseline to Weeks 12 and 48
|
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is a physician-assessed index used to evaluate systemic disease activity in Sjögren's disease. The total score ranges from 0 to 123, with higher scores indicating greater systemic disease activity. A decrease from baseline indicates improvement. |
Baseline to Weeks 12 and 48
|
|
Change from Baseline in EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Weeks 12, 24, and 48
Tidsram: Baseline to Weeks 12, 24, and 48
|
The EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is a patient-reported measure assessing dryness, fatigue, and pain. Each domain is rated on a 0-to-10 numerical rating scale, and the total ESSPRI score is calculated as the mean of the three domain scores, ranging from 0 to 10. Higher scores indicate greater symptom severity. A decrease from baseline indicates improvement. |
Baseline to Weeks 12, 24, and 48
|
|
Change from Baseline in Stimulated Salivary Flow (sSF) Rate at Weeks 12, 24, and 48
Tidsram: Baseline to Weeks 12, 24, and 48
|
Stimulated salivary flow rate will be measured according to the protocol-specified procedure. An increase from baseline indicates an improvement in stimulated salivary gland function. |
Baseline to Weeks 12, 24, and 48
|
|
Change from Baseline in Schirmer Test at Week 48
Tidsram: Baseline to Week 48
|
The Schirmer test is used to assess tear production and is reported as the length of wetting of the test strip over 5 minutes, measured in millimeters (mm/5 min). Higher values indicate greater tear production. |
Baseline to Week 48
|
|
Change from Baseline in Sj?gren's Tool for Assessing Response (STAR) Score at Week 48
Tidsram: Baseline to Week 48
|
The Sj?gren's Tool for Assessing Response (STAR) is a composite assessment of treatment response in Sj?gren's disease incorporating systemic disease activity, patient-reported symptoms, and biological and glandular domains. Higher scores indicate a greater treatment response. |
Baseline to Week 48
|
|
Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Weeks 12, 24, and 48
Tidsram: Baseline to Weeks 12, 24, and 48
|
The FACIT-Fatigue scale is a 13-item patient-reported measure of fatigue. The total score ranges from 0 to 52, with higher scores indicating less fatigue and better functioning. An increase from baseline indicates improvement. |
Baseline to Weeks 12, 24, and 48
|
|
Change from Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) Index Score at Weeks 12, 24, and 48
Tidsram: Baseline to Weeks 12, 24, and 48
|
The EQ-5D-5L is a standardized measure of health status assessing five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels of severity. Responses are converted to an EQ-5D-5L index score using the prespecified value set, with higher index scores indicating better health status. |
Baseline to Weeks 12, 24, and 48
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Tidsram: From the first dose of study intervention through Week 48
|
The number and percentage of participants experiencing treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) will be assessed throughout the study. |
From the first dose of study intervention through Week 48
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Muskuloskeletala sjukdomar
- Munsjukdomar
- Stomatogena sjukdomar
- Artrit
- Ledsjukdomar
- Reumatiska sjukdomar
- Bindvävssjukdomar
- Autoimmuna sjukdomar
- Immunsystemets sjukdomar
- Ögonsjukdomar
- Artrit, reumatoid
- Xerostomi
- Spottkörtelsjukdomar
- Torra ögon syndrom
- Sjukdomar i tårapparat
- Hud- och bindvävssjukdomar
- Sjögrens syndrom
- telitacicept
Andra studie-ID-nummer
- CIBI355A201
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .